JPWO2021263134A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021263134A5 JPWO2021263134A5 JP2022580315A JP2022580315A JPWO2021263134A5 JP WO2021263134 A5 JPWO2021263134 A5 JP WO2021263134A5 JP 2022580315 A JP2022580315 A JP 2022580315A JP 2022580315 A JP2022580315 A JP 2022580315A JP WO2021263134 A5 JPWO2021263134 A5 JP WO2021263134A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- concentration
- polypeptide
- modified fgf
- polysorbate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 13
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 229950008882 polysorbate Drugs 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 238000010268 HPLC based assay Methods 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims 1
- 239000013628 high molecular weight specie Substances 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 239000002357 osmotic agent Substances 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011179 visual inspection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044980P | 2020-06-26 | 2020-06-26 | |
| US63/044,980 | 2020-06-26 | ||
| PCT/US2021/039139 WO2021263134A1 (en) | 2020-06-26 | 2021-06-25 | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023532046A JP2023532046A (ja) | 2023-07-26 |
| JP2023532046A5 JP2023532046A5 (https=) | 2024-07-02 |
| JPWO2021263134A5 true JPWO2021263134A5 (https=) | 2024-07-02 |
Family
ID=79281929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022580315A Pending JP2023532046A (ja) | 2020-06-26 | 2021-06-25 | 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240024421A1 (https=) |
| EP (1) | EP4172351A4 (https=) |
| JP (1) | JP2023532046A (https=) |
| KR (1) | KR20230066318A (https=) |
| CN (1) | CN116710568A (https=) |
| WO (1) | WO2021263134A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4621067A3 (en) | 2017-05-05 | 2025-11-19 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
| TWI865835B (zh) * | 2020-11-16 | 2024-12-11 | 雅祥生技醫藥股份有限公司 | 穩定的酸性纖維母細胞生長因子組合物 |
| US20230022990A1 (en) * | 2021-05-14 | 2023-01-26 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
| WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
| AU2024247068A1 (en) * | 2023-03-28 | 2025-10-16 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
| CN116392441B (zh) * | 2023-04-21 | 2023-11-28 | 上海腾瑞制药股份有限公司 | 一种酸性成纤维细胞生长因子滴眼液制剂 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022758A (en) * | 1973-06-19 | 1977-05-10 | Ab Kabi | Isolation of coagulation factors I and VIII from biological material |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
| US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
| JP2009534390A (ja) * | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| US20080125580A1 (en) * | 2006-07-14 | 2008-05-29 | Genentech, Inc. | Refolding of Recombinant Proteins |
| ES2516694T3 (es) * | 2006-07-21 | 2014-10-31 | Ratiopharm Gmbh | Glicosilación de péptidos a través de secuencias de glicosilación con unión en O |
| US7696171B1 (en) | 2006-11-09 | 2010-04-13 | The Florida State University Research Foundation, Inc. | Mutant polypeptides of fibroblast growth factor 1 |
| US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
| CA2796459C (en) * | 2010-04-16 | 2016-05-24 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf-1 |
| US9714291B2 (en) * | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
| EP3419599A4 (en) * | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| EP4621067A3 (en) * | 2017-05-05 | 2025-11-19 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
| CN111315886A (zh) * | 2017-06-23 | 2020-06-19 | 珠海亿胜生物制药有限公司 | 重组人碱性成纤维细胞生长因子(rh-bFGF)以及包含rh-bFGF的药物组合物 |
| US11103552B2 (en) * | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
-
2021
- 2021-06-25 EP EP21829103.7A patent/EP4172351A4/en active Pending
- 2021-06-25 CN CN202180053250.XA patent/CN116710568A/zh active Pending
- 2021-06-25 KR KR1020237002819A patent/KR20230066318A/ko not_active Withdrawn
- 2021-06-25 JP JP2022580315A patent/JP2023532046A/ja active Pending
- 2021-06-25 WO PCT/US2021/039139 patent/WO2021263134A1/en not_active Ceased
-
2022
- 2022-12-21 US US18/069,585 patent/US20240024421A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102395379B (zh) | 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂 | |
| KR102340750B1 (ko) | 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제 | |
| JP4426646B2 (ja) | 表皮ケラチン細胞成長因子の類縁体 | |
| JPS60226821A (ja) | 化学修飾リンホカインおよびその製造法 | |
| US20070021342A1 (en) | Wound Healing | |
| SK284391B6 (sk) | Mutantné proteíny ľudského interleukínu-4 ako antagonisty alebo parciálne agonisty ľudského interleukínu-4, liečivá, ktoré ich obsahujú, a použitie | |
| Ozaki et al. | Amino acid sequence of a purothionin homolog from barley flour | |
| JPH08511682A (ja) | 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用 | |
| JPWO2021263134A5 (https=) | ||
| JP2002507546A (ja) | 角質細胞増殖因子−２の治療的使用 | |
| Rees et al. | Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions | |
| DeChiara et al. | Structure-function analysis of murine interleukin 1: biologically active polypeptides are at least 127 amino acids long and are derived from the carboxyl terminus of a 270-amino acid precursor. | |
| US6497869B2 (en) | Stabilized granulocyte colony stimulating factor | |
| JP3470135B2 (ja) | 成長ホルモンの結晶体を製造する方法およびそれにより得られる結晶体 | |
| WO2023164898A1 (zh) | 一种重组融合蛋白的制剂 | |
| CN110891591A (zh) | 用于治疗干眼症的包含甘氨酸-胸腺素β4(Gly-Tβ4)的药物组合物 | |
| EP1173194B1 (en) | Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation | |
| JP3350604B2 (ja) | ヒルジン含有医薬組成物 | |
| JPH0327320A (ja) | ヒトｂ細胞分化因子医薬組成物 | |
| JP2001026548A (ja) | ヒルジンを含んでなる医薬組成物 | |
| JPH10330283A (ja) | 消化管組織再生賦活剤 | |
| Horwitz et al. | rBPI (10—193) is secreted by CHO cells and retains the activity of rBPI21 | |
| JPH06247870A (ja) | インターロイキン−６を含有する医薬製剤 | |
| KR19980702956A (ko) | 트롬보포이에틴(ｔｐｏ)의 흡착방지방법 및 안정한 ｔｐｏ 함유조성물 | |
| JPWO1996028182A1 (ja) | Ｔｐｏの吸着防止方法および安定なｔｐｏ含有組成物 |